Low diabetes risk from medium-term PCSK9 inhibition
medwireNews: Pooled data from the ODYSSEY phase III trials show that PCSK9 inhibition does not result in excess cases of new-onset diabetes during up to 18 months of treatment, despite mounting evidence that lowering cholesterol levels increases diabetes risk.
Across the 10 phase III studies, the diabetes incidence rates per 100 patient–years were 1.2 and 1.8 among patients taking alirocumab in placebo-controlled and ezetimibe-controlled trials, respectively, and 1.8 and 2.8 in the corresponding control groups. The studies involved nearly 3500 patients in total.
The analysis in the European Heart Journal also shows no treated-related differences in glycated haemoglobin levels throughout follow-up.
The effect of statin treatment on diabetes risk only become apparent with long follow-up of large numbers of patients. But Helen Colhoun (University of Edinburgh, UK) and co-researchers say that the ODYSSEY OUTCOMES trial, involving around 18,000 patients treated for 2–5 years, will provide longer-term data for PCSK9 inhibition.
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016